FinBERT, a financial-language model, scores this headline as positive (93% confidence). That is the news tone only — not the full stock rating.
Stocks › DNLI
Denali Therapeutics Inc. (DNLI) stock analysis
SKIP 4% confidence · analysed Oct 30, 2026
On Oct 30, 2026, our model rated Denali Therapeutics Inc. (DNLI) SKIP with 4% confidence at a price of $19.27. That means the signals cancel out; the model sees no clear edge either way.
Analysed price$19.27
Technical picture
The 14-day RSI is 53, close to the neutral 50 line, so momentum is balanced.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is only 0.1x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure: bullish structure intact, no fresh break.
The most recent swing high is $27.30 and the swing low is $17.71; traders often treat these as resistance and support.
Price is sitting in a bearish order block, a zone where large sellers stepped in before, so upside may stall here.
Fundamentals
The company reports a profit margin of 0.0%.
In its latest quarter it earned $-0.68 per share, which missed the $-0.47 analysts expected.
Wall Street's average rating is 1.2 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $35.50.
The next earnings report is expected around Nov 3, 2026; prices often move sharply around earnings.
The model's one-paragraph read
No clear edge (SKIP) — composite score +0.04 (SKIP). Technicals: RSI 53.15, MACD bullish, price below SMA50. Fundamentals: margin 0.0%. Financial results: last EPS surprise -44.7%, next earnings 2026-11-03. Smart Money Concepts: bullish structure intact, no fresh break, price retesting a bearish order block. FinGPT news read: positive. Reference price $19.23; no trade levels (SKIP).
Past ratings for DNLI
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 30, 2026 | SKIP | 4% | $19.27 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on DNLI
Oct 30, 2026 · Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH (tividenofusp alfa-eknm) as Best Biotechnology Product
- Oct 30, 2026: Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH (tividenofusp alfa-eknm) as Best Biotechnology Product (GlobeNewswire)
Frequently asked questions
Is DNLI a buy right now?
As of Oct 30, 2026, our automated model rates Denali Therapeutics Inc. (DNLI) SKIP with 4% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
When does Denali Therapeutics Inc. report earnings next?
The next earnings report is expected around Nov 3, 2026.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.